Oncology

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

125

total

725.353

impact factor

5.803

average impact factor

Group Leaders: Soledad Gallego and Josep Sánchez de Toledo

team

zoom

download

In 2018, the group of Translational Research in Child and Adolescent Cancer has consolidadted their research lines, namely research on Soft Tissue Sarcomas (e.g. Rhabdomyosarcoma), Neural tumours (e.g. Neuroblastoma, Ependymoma) and the program of personalized medicine. This research yielded the publication of 21 new international papers with an accumulated impact factor (JCI 2017) of 145.073. The group has also been awarded with 2 new grants from Ministerio Economía, Industria y Competitividad, one grant from Instituto de Salud Carlos III, one grant form Asociación Española Contra el Cáncer-LABAECC and one grant from ITCC that will start on 2019. The group has continued with the consolidated collaborations with biotech companies to test and develop new therapies against the most aggressive pediatric solid tumors. These collaborations led to the filling of one patent during 2018.

Furthermore, the group is currently running 35 clinical trials with the most advanced treatments for childhood tumors.

20

total

139^.427

impact factor

6^.971

average impact factor

SELECTED ARTICLES

Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL;
European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
Lancet Oncol. 2018 Aug;19(8):1061-1071.
DOI: 10.1016/S1470-2045(18)30337-1.
IF: 36.4
Gambera S, Abarrategi A, González-Camacho F, Morales-Molina Á, Roma J, Alfranca A,, García-Castro J.
Clonal dynamics in osteosarcoma defined by RGB marking.
Nat Commun. 2018 Sep 28;9(1):3994.
DOI: 10.1038/s41467-018-06401-z
IF: 12.4
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L.
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Lancet Haematol. 2018 Oct;5(10):e450-e461.
DOI: 10.1016/S2352-3026(18)30153-4
IF: 10.7
Martínez-Ricarte F#, Mayor R#, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA,, López-Bigas N, Ramon Y Cajal S,, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J.
Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819.
DOI: 10.1158/1078-0432.CCR-17-3800
IF:10.2
Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R,, Roma J, Toledo JS,, Gallego S,, Segura MF.
Targeting of epigenetic regulators in neuroblastoma.
Exp Mol Med. 2018 Apr 27;50(4):51.
DOI: 10.1038/s12276-018-0077-2
IF: 5.58

View all publications

Oncology

Overview

Publications

Group Leaders: Soledad Gallego and Josep Sánchez de Toledo

Research Areas